Rivio closes its Series A with US$33 million raised and a US$200 million valuation, one year after its founding

São Paulo, October 2026. Rivio, an AI healthtech focused on hospital efficiency through artificial intelligence, has closed the extension of its Series A, raising R$180 million (about US$33 million) in a round led by Valor Capital Group. With the deal, the company reaches a valuation above R$1 billion (US$200 million), just over a year after its founding in 2025. Last December, its valuation had already passed R$500 million (about US$90 million).

The new round brings together Valor Capital Group, Monashees, Positive Ventures and APL, and marks continued investor support for Rivio. In earlier rounds, the company also received funding from Endeavor Catalyst. The reinvestment comes amid the growth of its operations and the fast adoption of its solutions by leading hospitals such as Albert Einstein, Sírio-Libanês, São Camilo and Oswaldo Cruz, reinforcing the bet on a model that applies AI to complex administrative processes in healthcare.

Rivio's starting point is the revenue cycle, which covers the steps between delivering care and hospitals getting paid. In this operation, artificial intelligence agents analyze information, support claims review and identify inconsistencies that can cause billing losses or payment delays. The technology works alongside healthcare specialists, who run the operation and handle the specifics of hospital processes.

This combination is central to the company's business model. While the sector spent decades buying software and running operations on its own, Rivio takes on the execution of processes alongside the hospital, is accountable for the outcome and guarantees payment from health plans for the services provided, with its compensation tied to that outcome. As a result, hospitals that work with Rivio have artificial intelligence as a structural part of the process, which drastically reduces manual work, makes cash flow more predictable and frees up more resources for patient care.

Rivio was founded by Ricardo Sales and Silvio Frison. Ricardo Sales co-founded the fintech isaac, acquired by Arco Educação for US$150 million. Silvio Frison was CEO of Serasa Consumidor, a business that reached more than 90 million users in Brazil. Rivio's ambition is to become the leading operating system for healthcare in Latin America. The revenue cycle is the first front of that strategy. The company plans to take its model to other areas of hospital administration, such as staffing, beds and supplies.

“Brazil operates on patients with robots and runs hospitals on spreadsheets. That math does not add up, and the patient pays the price. Rivio will bring to management the excellence our medicine already has.”

The company already operates in 13 hospital groups. Among the institutions it publicly lists as clients are Hospital Israelita Albert Einstein, Hospital Sírio-Libanês, Hospital Alemão Oswaldo Cruz, A.C.Camargo Cancer Center, Hcor, Hospital São Camilo and AACD.

Investors double down on Rivio's expansion

For the funds, Rivio's presence in leading institutions and the speed at which its technology is being adopted point to room to expand the company's footprint in Brazil. The possibility of applying the same model to other hospital management routines and, in the future, to other markets is part of the growth outlook behind the new investment.

“Brazilian hospitals still run on a technology infrastructure that has not kept pace with the complexity of the care they deliver. Rivio is rebuilding that foundation with artificial intelligence, led by extraordinary founders. The fact that some of the country's leading institutions signed on so quickly shows the sector was ready for this change. Increasing our investment is a bet on this team's ability to redesign healthcare in Brazil,” says Carlos Costa of Valor Capital Group.

Founders and advisory board bring together technology and healthcare experience

Rivio recently set up an advisory board of nine healthcare, management and technology leaders. The group includes Henrique Neves, CEO of Einstein and vice chair of Anahp's Board of Directors; Paulo Chapchap, former CEO of Hospital Sírio-Libanês and current medical director at IEPS; José Marcelo de Oliveira, CEO of Hospital Alemão Oswaldo Cruz; and Teresa Sacchetta, a physician trained at USP and vice president of Conselho Saúde Digital Brasil.

The board also includes Luiz De Luca, former CEO of Hospital 9 de Julho and an executive with broad experience in hospital management; Gustavo Meirelles, Chief Medical and Institutional Relations Officer at Afya; and Fernando Carneiro, senior partner at Vila Nova Partners, former head of Latin America at Spencer Stuart and former executive director of Febraban.

On the technology side, the board includes people who built their careers in Silicon Valley and at companies driving the advance of AI. Among them are Mat Velloso, currently Chief Product Officer at Docker, with roles at Microsoft, Google and Meta, where he was vice president of Product; and River Mist, a member of OpenAI's Emerging Products team, which he joined after the acquisition of Weights, the company he founded.

• Henrique NevesEinstein CEO for 20 years
• Mat VellosoGoogle DeepMind · Microsoft · Meta
• Paulo ChapchapSírio-Libanês CEO for nearly 20 years
• River MistOpenAI · Founder Weights.gg
• José Marcelo de OliveiraCEO, Oswaldo Cruz
• Teresa SacchettaFormer CIO, Fleury · Sírio · UnitedHealth
• Luiz De Luca40+ years in hospital management
• Gustavo MeirellesLeader at Afya, the largest medical education hub
• Fernando Carneiro25+ years in executive search

For Ricardo Sales, co-founder of Rivio, the advance of artificial intelligence has the potential to radically change the way hospitals are run.

“Brazilian healthcare needs a new management infrastructure, and we now have the technology to make it happen. We are bringing together the best engineering talent in Brazil and world-class leaders in healthcare and artificial intelligence to take on this challenge. The potential is immense: more efficient hospitals can invest more in treatment and save lives. Our investors saw this opportunity within a few months and decided to double down.”